Remsima/Inflectra (infliximab biosimilar CT-P13)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Remsima/Inflectra (infliximab biosimilar CT-P13), covering 2017-08-01 to 2017-08-01. Get the full timeline:
Most recent: Clinical Trial Update: An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1 [Phase 3]